Inozyme Pharma Statistics
Share Statistics
Inozyme Pharma has 64.56M
shares outstanding. The number of shares has increased by 3.86%
in one year.
| Shares Outstanding | 64.56M |
| Shares Change (YoY) | 3.86% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 82.8% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,367 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 3.84M, so 5.94% of the outstanding
shares have been sold short.
| Short Interest | 3.84M |
| Short % of Shares Out | 5.94% |
| Short % of Float | 6.42% |
| Short Ratio (days to cover) | 1.71 |
Valuation Ratios
The PE ratio is -1.71 and the forward
PE ratio is -3.46.
Inozyme Pharma's PEG ratio is
-0.09.
| PE Ratio | -1.71 |
| Forward PE | -3.46 |
| PS Ratio | 0 |
| Forward PS | 1.2 |
| PB Ratio | 3.01 |
| P/FCF Ratio | -1.89 |
| PEG Ratio | -0.09 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Inozyme Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.56,
with a Debt / Equity ratio of 0.81.
| Current Ratio | 3.56 |
| Quick Ratio | 3.56 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | -0.45 |
| Debt / FCF | -0.51 |
| Interest Coverage | 18.72 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,522,746.27 |
| Employee Count | 67 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -15.57% in the
last 52 weeks. The beta is 1.34, so Inozyme Pharma's
price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | -15.57% |
| 50-Day Moving Average | 1.57 |
| 200-Day Moving Average | 2.9 |
| Relative Strength Index (RSI) | 85.75 |
| Average Volume (20 Days) | 2,006,878 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -104.03M |
| Net Income | -102.02M |
| EBITDA | -104.03M |
| EBIT | -107.58M |
| Earnings Per Share (EPS) | -1.62 |
Full Income StatementBalance Sheet
The company has 21.08M in cash and 46.87M in
debt, giving a net cash position of -25.79M.
| Cash & Cash Equivalents | 21.08M |
| Total Debt | 46.87M |
| Net Cash | -25.79M |
| Retained Earnings | -387.95M |
| Total Assets | 95.16M |
| Working Capital | 50.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -91.91M
and capital expenditures -62K, giving a free cash flow of -91.97M.
| Operating Cash Flow | -91.91M |
| Capital Expenditures | -62K |
| Free Cash Flow | -91.97M |
| FCF Per Share | -1.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
